VBI Vaccines Inc. announced the initiation of enrollment in the Phase 1 clinical study of VBI-2901, a multivalent enveloped virus-like particle (eVLP) coronavirus vaccine candidate expressing the full-length spike proteins from the SARS-CoV-1 (SARS), SARS-CoV-2 (COVID-19), and MERS-CoV (MERS) viruses. Coronaviruses are enveloped viruses by nature, making them prime targets for VBI's flexible eVLP technology, which in a Phase 1a/1b study of two monovalent, variant-specific vaccine candidates generated human proof-of- concept data demonstrating the safety, tolerability, and immunogenicity of the eVLP platform against coronaviruses. The Phase 1 randomized, open-label study will enroll three cohorts of subjects, randomized 1:1:1, to compare either two intramuscular doses of VBI-2901 at a low- (5µg) or high- (10µg) dose level, or one dose of VBI-2901 at the high-dose level (10µg) in approximately 100 healthy adults age 18-64 who have previously received two or more immunizations with COVID-19 vaccines licensed by Health Canada.

Each participant must have received their previous dose of a licensed COVID-19 vaccine at least six months prior to study enrollment. This study is supported by funding from the Government of Canada's Innovation, Science and Economic Development (ISED) through the Strategic Innovation Fund.